EHA 2016 Multiple Myeloma Satellite Symposia
There will be seven multiple myeloma-related satellite symposia conducted in association with the 2016 European Hematology Association (EHA) annual meeting in Copenhagen, Denmark. All symposia will take place on Thursday, June 9, which is the day prior to the official start of the meeting.
They symposia are generally sponsored by major pharmaceutical companies. They offer attendees the opportunity to hear leading myeloma-researchers share their perspectives on key myeloma-related issues.
Information about each of the seven satellite symposia is listed below.
| Session |
Novartis Oncology - On the Mark: Targeting Epigenetics for the Treatment of Multiple Myeloma |
| Type | Satellite Symposium (more information on this session) |
| Time | Thursday June 9, 8:00 AM to 10:00 AM |
| Location | Hall A1 |
| Chair | M Dimopoulos |
| A Spencer |
Introduction |
| A Spencer |
Rationale for HDAC inhibition in multiple myeloma and clinical experience with pan-HDAC inhibitors |
| J Shah |
Novel combinations of HDAC and proteasome inhibitors |
| E Ocio |
HDAC inhibitors in combination with immunomodulatory drugs: preclinical evidence and clinical development |
| K Yong |
Targeting epigenetics in multi-drug combinations for relapsed/refractory, frontline, and maintenance therapy |
| Session |
prIME Oncology - The Matrix of Care: Navigating Complex Therapeutic Strategies for Multiple Myeloma in 2016 |
| Type | Satellite Symposium (more information on this session) |
| Time | Thursday June 9, 8:00 AM to 10:00 AM |
| Location | Hall C11 |
| Chair | J San Miguel |
| J San Miguel |
Welcome And Introduction |
| J San Miguel |
Understanding the heterogeneity of multiple myeloma: A key to future success |
| S Kumar |
Making the most of initial therapy of multiple myeloma: What’s new? |
| P Richardson |
Consolidation and maintenance therapy for multiple myeloma: Is it the new standard? |
| M Dimopoulos |
Relapsed/refractory multiple myeloma |
| M Boccadoro |
What’s on the horizon? |
| Session |
Takeda Oncology - Navigating the Changing Multiple Myeloma Treatment Landscape |
| Type | Satellite Symposium (more information on this session) |
| Time | Thursday June 9, 10:45 AM to 12:45 PM |
| Location | Hall C13 |
| Chair | P Richardson |
| P Richardson |
Welcome and Introduction |
| P Richardson |
Exploring recent developments in multiple myeloma therapeutics |
| TBD |
Evolving treatment paradigms in multiple myeloma |
| R Hajek |
Preventing clonal evolution in multiple myeloma – evidence from clinical trials |
| A Palumbo |
Continuous therapy: Are we there yet? |
| TBD |
Examining the evidence for ixazomib in multiple myeloma treatment |
| S Kumar |
The ixazomib development journey |
| P Richardson |
The Phase 3 TOURMALINE-MM1 study |
| P Richardson |
Summary and Close |
| Session |
Celgene - Unravelling Treatment Options in Multiple Myeloma Care |
| Type | Satellite Symposium (more information on this session) |
| Time | Thursday June 9, 10:45 PM to 12:45 PM |
| Location | Hall A1 |
| Chair | J San Miguel |
| J San Miguel |
Welcome and introduction |
| T Facon |
Evolving treatment concepts for long-term disease control in NDMM |
| G Morgan |
Treatment strategies at first relapse: How to individualize therapy |
| K Weisel |
Treatment approaches for advanced disease: Impact of prior lines and novel agents |
| J San Miguel |
Breakthroughs in immuno-oncology: Overcoming disruptions in the multiple myeloma immune environment |
| J San Miguel |
Summary and close |
| Session |
Bristol-Myers Squibb - The Hematology Evolution: Forging Ahead in Multiple Myeloma |
| Type | Satellite Symposium (more information on this session) |
| Time | Thursday June 9, 1:30 PM to 3:30 PM |
| Location | Hall A3 |
| Chair | S Lonial |
| S Lonial |
Welcome and Introductions |
| D Reece |
Making Progress with Immuno-Oncology (I-O) |
| N van de Donk |
From Past to Present: Multiple Myeloma in Review |
| S Lonial |
The Future of Multiple Myeloma: I-O and More |
| M Mohty |
Part 1: Considerations for Multiple Myeloma in Clinical Practice (Rapidly Progressing Relapsed Refractory Disease) |
| K Weisel |
Part 2: Considerations for Multiple Myeloma in Clinical Practice (Slowly Progressing Relapsed Refractory Disease) |
| S Lonial |
Concluding Remarks |
| Session |
Janssen - Raising the Bar in Multiple Myeloma Management |
| Type | Satellite Symposium (more information on this session) |
| Time | Thursday June 9, 1:30 PM to 3:30 PM |
| Location | Hall A1 |
| Chair | J San Miguel |
| J San Miguel |
Is it time to reassess current endpoints and the role of MRD in MM? |
| M Cavo |
Optimising management of transplant eligible patients in 2016 |
| A Palumbo |
Current considerations for patients not eligible for transplantation |
M Dimopoulos |
Redefining the landscape in relapsed and refractory MM with monoclonal antibodies |
| P Richardson |
How are treatment paradigms changing across the Atlantic: a US perspective on improving outcomes for patients |
| Session |
Amgen - Looking to the Future: A Debate on the Transforming Myeloma Treatment Landscape |
| Type | Satellite Symposium (more information on this session) |
| Time | Thursday June 9, 4:15 PM to 6:15 PM |
| Location | Hall C11 |
| Chair | M Dimopoulos |
| M Dimopoulos |
Welcome and introduction |
Debate 1: Triplet combinations for relapsed multiple myeloma patients: the new standard? |
|
| J San-Miguel |
Introduction to motion and initial audience vote |
| A Palumbo |
Argument for the motion |
| M Dimopoulos |
Argument against the motion |
| A Palumbo & M Dimopoulos |
Rebuttals |
| J Bladé |
Summary and audience vote |
Debate 2 MRD-guided therapy: the future for all patients? |
|
| M Dimopoulos |
Introduction to motion and initial audience vote |
| J Bladé |
Argument for the motion |
| S Kumar |
Argument against the motion |
| J Bladé & S Kumar |
Rebuttals |
| M Dimopoulos |
Summary and audience vote |
| M Dimopoulos |
Summary and close |
